Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 16/20 | 0.49 |
| ▸ | HRH1 | P35367 | 16/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658546 | 0.81 | CCR3 (0.68) | CCR3HRH1KCNH2EPHX2 | |
| SCHEMBL13176904 | 0.79 | CCR3 (0.61) | CCR3HRH1KCNH2EPHX2 | |
| SCHEMBL5369784 | 0.79 | HRH1 (0.53) | CCR3HRH1KCNH2FPR2PROKR1 | |
| SCHEMBL5372694 | 0.78 | CCR3 (0.53) | CCR3HRH1KCNH2FPR2PROKR1 | |
| SCHEMBL5367457 | 0.78 | HRH1 (0.52) | CCR3HRH1KCNH2FPR2PROKR1 | |
| SCHEMBL5364002 | 0.78 | CCR3 (0.53) | CCR3HRH1KCNH2FPR2PROKR1 | |
| SCHEMBL3284215 | 0.74 | HRH1 (0.70) | CCR3HRH1KCNH2 | |
| SCHEMBL3284211 | 0.74 | HRH1 (0.70) | CCR3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL5656041 | 0.74 | CCR3 (0.75) | CCR3HRH1KCNH2EPHX2 | |
| SCHEMBL2920721 | 0.74 | HRH1 (0.73) | CCR3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348341-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20030166652-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1289956-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092227-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166652-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CCR3 1/4885HRH1 1080/4885KCNH2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.